MCID: CYS014
MIFTS: 47

Cystadenocarcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Cystadenocarcinoma

Aliases & Descriptions for Cystadenocarcinoma:

Name: Cystadenocarcinoma 12 52 42 14 69
Cystadenocarcinoma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3111
MeSH 42 D003536
NCIt 47 C2971
SNOMED-CT 64 189681005 21008007
UMLS 69 C0010631

Summaries for Cystadenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Cystadenocarcinoma, also known as cystadenocarcinoma nos, is related to breast mucinous cystadenocarcinoma and appendix mucinous cystadenocarcinoma. An important gene associated with Cystadenocarcinoma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are WNT Signaling and Colorectal Cancer Metastasis. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and liver, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and cellular

Wikipedia : 71 Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from... more...

Related Diseases for Cystadenocarcinoma

Diseases related to Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
id Related Disease Score Top Affiliating Genes
1 breast mucinous cystadenocarcinoma 32.9 CEACAM5 FSHR ZNF217
2 appendix mucinous cystadenocarcinoma 31.7 FSHR KRT7 MUC1 MUC2 PTPRC SLCO4A1
3 endocervicitis 28.8 AKT1 BIRC5 ESR2 FSHR PGR VEGFA
4 mucinous cystadenocarcinoma 12.3
5 serous cystadenocarcinoma 12.3
6 papillary cystadenocarcinoma 12.2
7 ovarian mucinous cystadenocarcinoma 12.0
8 ovarian cystadenocarcinoma 12.0
9 bile duct cystadenocarcinoma 11.9
10 pancreatic serous cystadenocarcinoma 11.9
11 ovarian serous cystadenocarcinoma 11.9
12 pancreatic cystadenocarcinoma 11.9
13 acinar cell cystadenocarcinoma 11.9
14 mucinous cystadenocarcinoma of pancreas 11.9
15 pancreatic non-invasive mucinous cystadenocarcinoma 11.7
16 ovarian clear cell cystadenocarcinoma 11.7
17 pancreatic colloid cystadenocarcinoma 11.6
18 pancreatic invasive mucinous cystadenocarcinoma 11.6
19 multilocular clear cell renal cell carcinoma 10.9
20 appendix adenocarcinoma 10.8
21 papillary serous adenocarcinoma 10.7
22 multilocular cystic clear cell renal cell neoplasm of low malignant potential 10.7
23 pancreatitis 10.3
24 bronchogenic lung adenocarcinoma 10.3 CEACAM5 MUC1
25 cystadenoma 10.3
26 lymphoplasmacyte-rich meningioma 10.3 CEACAM5 PGR
27 marfanoid hypermobility syndrome 10.3 MUC1 PGR VIM
28 endometrial stromal sarcoma 10.3 MUC1 PGR VIM
29 bladder adenocarcinoma 10.3 MUC1 PGR VIM
30 lacrimal gland mucoepidermoid carcinoma 10.3 CEACAM5 MUC1 PGR
31 sebaceous adenoma 10.3 MUC1 PGR VIM
32 mesenchymoma 10.3 MUC1 PGR VIM
33 lymphomatous thyroiditis 10.3 PGR VIM
34 precursor lymphoblastic lymphoma/leukemia 10.3 KRT7 PGR
35 scirrhous adenocarcinoma 10.3 MUC1 PGR VIM
36 jewett-marshall bladder cancer 10.2 CEACAM5 PGR VIM
37 sclerosing hemangioma 10.2 MUC1 MUC2 PGR
38 immunodeficiency due to a classical component pathway complement deficiency 10.2 BIRC5 MUC1 VIM
39 deep angioma 10.2 CEACAM5 KRT7
40 osteosarcoma arising in bone paget's disease 10.2 CEACAM5 KRT7
41 biemond syndrome 10.2 KRT7 PGR VIM
42 gestational ovarian choriocarcinoma 10.2 MUC1 MUC2
43 aortitis 10.2 PGR TP53
44 thymoma 10.2 CEACAM5 KRT7 MUC1
45 vulva basal cell carcinoma 10.2 CEACAM5 KRT7 PGR
46 ovarian papillary neoplasm 10.2 KRT7 MUC1 VIM
47 malignant mediastinal neurogenic neoplasm 10.2 CEACAM5 TP53
48 anemia of prematurity 10.2 KRT7 MUC1 MUC2
49 acute thyroiditis 10.2 ESR2 FSHR PGR
50 sagittal sinus thrombosis 10.2 KRT7 MUC1 MUC2

Graphical network of the top 20 diseases related to Cystadenocarcinoma:



Diseases related to Cystadenocarcinoma

Symptoms & Phenotypes for Cystadenocarcinoma

GenomeRNAi Phenotypes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.02 VIM ALPP MUC1 PTPRC VEGFA

MGI Mouse Phenotypes related to Cystadenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 AKT1 BIRC5 ESR2 FSHR KRT7 MUC2
2 endocrine/exocrine gland MP:0005379 9.97 AKT1 BIRC5 ESR2 FSHR MUC2 PGR
3 hematopoietic system MP:0005397 9.96 MUC2 PGR PTPRC TP53 VEGFA VIM
4 homeostasis/metabolism MP:0005376 9.9 AKT1 BIRC5 ESR2 FSHR KRT7 MUC2
5 immune system MP:0005387 9.65 AKT1 BIRC5 ESR2 FSHR MUC2 PGR
6 neoplasm MP:0002006 9.23 PGR PTPRC TP53 VEGFA AKT1 ESR2

Drugs & Therapeutics for Cystadenocarcinoma

Drugs for Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
6
Levoleucovorin Approved Phase 3,Phase 2,Phase 1 68538-85-2
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
12
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
13
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
14
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
15
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
16
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
17
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
18
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
19
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 14219 4091
20
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
21
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
22
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
24
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
25
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
26
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
27
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
28
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
29
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
30 Alkylating Agents Phase 3,Phase 2,Phase 1
31 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
32 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
34 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
35 Antidotes Phase 3,Phase 2,Phase 1
36 Antimetabolites Phase 3,Phase 2,Phase 1
37 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
39 Calcium, Dietary Phase 3,Phase 2,Phase 1
40 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
41 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
42 Mitomycins Phase 3
43 Nucleic Acid Synthesis Inhibitors Phase 3
44 Protective Agents Phase 3,Phase 2,Phase 1
45 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Trace Elements Phase 3,Phase 2,Phase 1,Early Phase 1
48 Vitamin B Complex Phase 3,Phase 2,Phase 1
49 Vitamins Phase 3,Phase 2,Phase 1,Early Phase 1
50
Cobalt Phase 3 7440-48-4 104729

Interventional clinical trials:

(show top 50) (show all 171)
id Name Status NCT ID Phase
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3
3 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
4 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
7 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
8 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
9 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
10 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
11 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
12 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
13 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
14 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
15 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3
16 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
17 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3
18 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
19 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
20 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3
21 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
22 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
23 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3
24 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3
25 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
26 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not yet recruiting NCT02839707 Phase 2, Phase 3
27 Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery Terminated NCT00068692 Phase 3
28 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3
29 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3
30 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
31 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2
32 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2
33 Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Unknown status NCT01079780 Phase 2
34 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2
35 Toremifene in Treating Patients With Ovarian Cancer Completed NCT00003865 Phase 2
36 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2
37 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2
38 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2
39 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2
40 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
41 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2
42 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2
43 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2
44 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2
45 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
46 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2
47 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2
48 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2
49 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2
50 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2

Search NIH Clinical Center for Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma

Genetic Tests for Cystadenocarcinoma

Anatomical Context for Cystadenocarcinoma

MalaCards organs/tissues related to Cystadenocarcinoma:

39
Ovary, Pancreas, Liver, Appendix, Salivary Gland, Breast, Colon

Publications for Cystadenocarcinoma

Articles related to Cystadenocarcinoma:

(show top 50) (show all 666)
id Title Authors Year
1
Contrast enhanced ultrasound features of hepatic cystadenoma and hepatic cystadenocarcinoma. ( 27887203 )
2017
2
Recto-vaginal septum cystadenocarcinoma: a case report and review of the literature. ( 27142415 )
2016
3
Papillary Cystadenocarcinoma of the Parotid Gland: A Rare Case Report. ( 27504297 )
2016
4
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
5
Pancreatic mucinous cystadenocarcinoma: Epidemiology and outcomes. ( 27638187 )
2016
6
Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )
2016
7
Giant mucinous cystadenocarcinoma of ovary: A case report and review of literature. ( 27134482 )
2016
8
Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm. ( 27367953 )
2016
9
Degenerative hepatic hemangioma mimicking biliary cystadenocarcinoma. ( 26896817 )
2016
10
Mucinous Cystadenocarcinoma in a Horse Shoe Kidney Masquerading as Giant Hydronephrosis - A Case Report: Diagnostic Challenges, Lessons Learnt and Review of Literature. ( 28050435 )
2016
11
Cytomorphological findings and histological correlation of papillary cystadenocarcinoma of the parotid: Not always a low-grade tumor. ( 27510680 )
2016
12
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016
13
Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. ( 26681306 )
2016
14
Mucinous cystadenocarcinoma of the pancreas with anaplastic carcinoma: A case report and review of the literature. ( 27073646 )
2016
15
Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. ( 27166050 )
2016
16
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
17
Epididymal papillary cystadenocarcinoma metastasising to the testis in a patient with infertility managed with Onco-microTeSE. ( 27887012 )
2016
18
Low-grade cribriform cystadenocarcinoma arising from a minor salivary gland: a case report. ( 27021553 )
2016
19
Cytomorphological features of papillary cystadenocarcinoma of parotid gland: A case report with review of literature. ( 27298629 )
2016
20
Retraction note: Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade histopathologic malignancy. ( 27814773 )
2016
21
Clinicopathological characteristics, treatment, and survival outcomes of cystadenocarcinoma of the salivary gland: a population-based study. ( 27822061 )
2016
22
Radiologic Findings of Primary Mucinous Cystadenocarcinoma of the Breast: A Report of Two Cases and a Literature Review. ( 27721884 )
2016
23
A Rare biliary cystic tumors: a case series of biliary cystadenomas and cystadenocarcinoma. ( 27049501 )
2016
24
OK-432 injection therapy for cystadenocarcinoma of the parotid gland: A case report. ( 27140021 )
2016
25
A giant mucinous cystadenocarcinoma of the appendix: a case report and review of the literature. ( 26945579 )
2016
26
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
27
Cytology of low-grade cribriform cystadenocarcinoma in salivary glands: Cytological and immunohistochemical distinctions from other salivary gland neoplasms. ( 26875597 )
2016
28
Vaginal fold prolapse in a dog with pyometra and ovarian papillary cystadenocarcinoma. ( 27003024 )
2016
29
Cystic Epithelial Tumors of the Prostate: One Case Supporting a Continuous Spectrum From Cystadenoma to Cystadenocarcinoma With Ductal Features. ( 27631516 )
2016
30
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
31
Synchronous resection of pancreatic serous cystadenocarcinoma and liver metastasis: First reported case and review of literature. ( 26463518 )
2015
32
Primary mucinous cystadenocarcinoma of the renal pelvis misdiagnosed as ureteropelvic junction stenosis with renal pelvis stone: a case report and literature review. ( 26612470 )
2015
33
A Case Report of Partial Nephrectomy of Mucinous Cystadenocarcinoma in Kidney and Its Literature Review. ( 25687861 )
2015
34
"Sea anemone-like ciliated tumor cells" in a case of serous cystadenocarcinoma of the ovary. ( 26811576 )
2015
35
Hepatic Intracystic Organizing Hematoma Mimicking Biliary Cystadenocarcinoma in a Patient with Polycystic Liver Disease. ( 26278291 )
2015
36
Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. ( 26177796 )
2015
37
Biliary cystadenocarcinoma: an unusual cause for recurrent hemobilia. ( 25875554 )
2015
38
Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. ( 26259386 )
2015
39
Report of a case: Retroperitoneal mucinous cystadenocarcinoma with rapid progression. ( 25884614 )
2015
40
Primary mucinous cystadenocarcinoma of the testis: An extremely rare ovarian-type surface epithelial carcinoma. ( 26458610 )
2015
41
Low-grade cribriform cystadenocarcinoma of the palatal gland: A case report. ( 26622870 )
2015
42
Pathology in Practice. Concurrent metastatic mammary adenocarcinoma and ovarian cystadenocarcinoma in a jaguar. ( 26517614 )
2015
43
Primary Peritoneal Papillary Serous Cystadenocarcinoma - A Rare Malignancy. ( 26713835 )
2015
44
Identification of Differentially Expressed miRNAs in Appendiceal Mucinous Cystadenocarcinoma from Mucinous Cystadenoma. ( 26807210 )
2015
45
Mucinous Cystadenocarcinoma Co-Existing with Mature Cystic Teratoma : A Rare Case Report. ( 26393136 )
2015
46
Solid variant type of serous cystadenocarcinoma of the pancreas: AA case report and review of the literature. ( 25716800 )
2015
47
Spontaneous rupture of ovarian cystadenocarcinoma: pre- and post-rupture computed tomography evaluation. ( 26543286 )
2015
48
A rare tumor: mucinous cystadenocarcinoma of the breast. ( 25760182 )
2015
49
Hepatobiliary Cystadenocarcinoma of the Liver with Features of Ductal Plate Malformations. ( 25656967 )
2015
50
Management of a primary retroperitoneal mucinous cystadenocarcinoma: case report. ( 24772920 )
2014

Variations for Cystadenocarcinoma

Expression for Cystadenocarcinoma

Search GEO for disease gene expression data for Cystadenocarcinoma.

Pathways for Cystadenocarcinoma

GO Terms for Cystadenocarcinoma

Biological processes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular response to hypoxia GO:0071456 9.33 AKT1 TP53 VEGFA
2 negative regulation of apoptotic process GO:0043066 9.02 AKT1 BIRC5 CEACAM5 TP53 VEGFA
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.96 MUC1 TP53

Molecular functions related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 AKT1 BIRC5 CEACAM5 TP53 VEGFA VIM
2 enzyme binding GO:0019899 9.02 AKT1 BIRC5 ESR2 PGR TP53

Sources for Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....